Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bart Cornelissen is active.

Publication


Featured researches published by Bart Cornelissen.


PLOS ONE | 2011

Hypoxia Imaging Using PET and SPECT: The Effects of Anesthetic and Carrier Gas on [64Cu]-ATSM, [99mTc]-HL91 and [18F]-FMISO Tumor Hypoxia Accumulation

Veerle Kersemans; Bart Cornelissen; Rebekka Hueting; Matthew Tredwell; Kamila Hussien; Philip D. Allen; Nadia Falzone; Sally A. Hill; Jonathan R. Dilworth; Véronique Gouverneur; Ruth J. Muschel; Sean Smart

Background Preclinical imaging requires anaesthesia to reduce motion-related artefacts. For direct translational relevance, anaesthesia must not significantly alter experimental outcome. This study reports on the effects of both anaesthetic and carrier gas upon the uptake of [64Cu]-CuATSM, [99mTc]-HL91 and [18F]-FMISO in a preclinical model of tumor hypoxia. Methodology/Principal Findings The effect of carrier gas and anaesthetic was studied in 6 groups of CaNT-bearing CBA mice using [64Cu]-CuATSM, [99mTc]-HL91 or [18F]-FMISO. Mice were anaesthetised with isoflurane in air, isoflurane in pure oxygen, with ketamine/xylazine or hypnorm/hypnovel whilst breathing air, or in the awake state whilst breathing air or pure oxygen. PET or SPECT imaging was performed after which the mice were killed for organ/tumor tracer quantitation. Tumor hypoxia was confirmed. Arterial blood gas analysis was performed for the different anaesthetic regimes. The results demonstrate marked influences on tumor uptake of both carrier gas and anaesthetic, and show differences between [99mTc]-HL91, [18F]-FMISO and [64Cu]-CuATSM. [99mTc]-HL91 tumor uptake was only altered significantly by administration of 100% oxygen. The latter was not the case for [18F]-FMISO and [64Cu]-CuATSM. Tumor-to-muscle ratio (TMR) for both compounds was reduced significantly when either oxygen or anaesthetics (isoflurane in air, ketamine/xylazine or hypnorm/hypnovel) were introduced. For [18F]-FMISO no further decrease was measured when both isoflurane and oxygen were administered, [64Cu]-CuATSM did show an additional significant decrease in TMR. When using the same anaesthetic regimes, the extent of TMR reduction was less pronounced for [64Cu]-CuATSM than for [18F]-FMISO (40–60% versus 70% reduction as compared to awake animals breathing air). Conclusions/Significance The use of anaesthesia can have profound effects on the experimental outcome. More importantly, all tested anaesthetics reduced tumor-hypoxia uptake. Anaesthesia cannot be avoided in preclinical studies but great care has to be taken in preclinical models of hypoxia as anaesthesia effects cannot be generalised across applications, nor disease states.


Society of Nuclear Medicine Annual Meeting Abstracts | 2009

Amplification of IR-induced DNA damage by Auger electron treatment with TAT-radioimmunoconjugates

Bart Cornelissen; Sonali Darbar; Kate Sleeth; Veerle Kersemans; Katherine Vallis


Society of Nuclear Medicine Annual Meeting Abstracts | 2011

64Cu-ATSM is metabolised rapidly in vivo to yield circulating 64Cu2+ in blood in the mouse

Rebekka Hueting; Veerle Kersemans; Matthew Tredwell; Kamila Hussien; Bart Cornelissen; Nadia Falzone; Ruth J. Muschel; Jon Dilworth; Sean Smart; Véronique Gouverneur


Society of Nuclear Medicine Annual Meeting Abstracts | 2009

Imaging of DNA double strand breaks in vivo using fluorophore-labelled TAT-immunoconjugates

Bart Cornelissen; Veerle Kersemans; Kate Sleeth; Sonali Darbar; Sean Smart; Katherine Vallis


Society of Nuclear Medicine Annual Meeting Abstracts | 2013

Targeting {gamma}H2AX during oncogenesis with Auger electron therapy delays tumor onset

Bart Cornelissen; Sarah Able; Katherine Vallis


Society of Nuclear Medicine Annual Meeting Abstracts | 2012

Radiolabelled PEGylated nano-graphene oxide: Synthesis and SPECT imaging

Bart Cornelissen; Sarah Able; Veerle Kersemans; Sverre Myhra; Alison Crossley; Katherine Vallis


Society of Nuclear Medicine Annual Meeting Abstracts | 2012

Nano-graphene oxide as a scaffold for radioimmunoconjugates

Bart Cornelissen; Sarah Able; Veerle Kersemans; Sverre Myhra; Alison Crossley; Katherine Vallis


Society of Nuclear Medicine Annual Meeting Abstracts | 2012

Development of a Tat-conjugated anti-{gamma}H2AX Fab fragment SPECT probe to image DNA damage

Ketan A. Shah; Katherine Vallis; Bart Cornelissen


Society of Nuclear Medicine Annual Meeting Abstracts | 2012

Multimodality imaging demonstrates vessel-governed delivery of radiolabelled PEGylated nano-graphene oxide

Bart Cornelissen; Veerle Kersemans; Philip D. Allen; Sarah Able; Sverre Myhra; Alison Crossley; Sean Smart; Katherine Vallis


Society of Nuclear Medicine Annual Meeting Abstracts | 2011

Tumour-specific delivery of cleavable radiolabelled antibodies against intranuclear {gamma}H2AX

Bart Cornelissen; Andrew M. Waller; Veerle Kersemans; Nadia Falzone; Sean Smart; Katherine Vallis

Collaboration


Dive into the Bart Cornelissen's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Raymond Reilly

University Health Network

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kamila Hussien

Medical Research Council

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge